[Convulex and its place in epilepsy treatment with original valproates].
Therapeutic efficacy of three original valproates (convulex, depakine enteric and convulsofine) as well as direct cost of drugs for epilepsy treatment have been studied in 249 patients with long-term epilepsy with different types of epileptic seizures. The convulex efficacy was found to be lower than that of the other two drugs. Also, convulex reduces the frequency of seizures by 50-100% in 75% of the patients. During the convulex treatment of some types of seizures, remission was achieved in 81-90% of the patients. At the same time, the cost of treatment with convulex is 1.5 times lower comparing to that with depakine and is equal to that for convulsofine. The authors concluded the cost benefit of convulex treatment appeared to stimulate regional health departments and individual patients for wholesale and retail drug purchases.
Gromov
S A
SA
Kim
K V
KV
D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D003362:Cost-Benefit Analysis; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome; D014635:Valproic Acid / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*
D000927:Anticonvulsants; D014635:Valproic Acid